Navigation Links
CVS/pharmacy Teams Up with Access Hollywood for an Award Season Gifting Suite That Gives Back
Date:1/12/2009

Celebrities step out for a worthy cause at Access Hollywood's 3rd Annual "Stuff You Must" Lounge benefiting Best Buddies and Lollipop Theater Network.

LOS ANGELES, Jan. 12 /PRNewswire/ -- CVS/pharmacy, America's largest retail pharmacy, once again donated $100,000 to two important charities on behalf of celebrities attending Access Hollywood's "Stuff You Must" Lounge this weekend. The donations are a part of CVS/pharmacy's third consecutive beauty sponsorship of the lounge, which celebrates the nominees and presenters while giving back to the community.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090112/NE57766 )

Unlike many other gifting lounges during award season, the "Stuff You Must" lounge, produced by On 3 Productions, has a strong charitable component. In addition to the monetary donation from CVS/pharmacy, beneficiaries from the two affiliated charities - Best Buddies and Lollipop Theater Network - received the celebrity treatment with gift bags and pampering at CVS/pharmacy's spa and gifting suite at the lounge.

"CVS/pharmacy is dedicated to improving the lives of those in the communities we serve," said Eileen Howard Dunn, Senior Vice President of Corporate Communications and Community Relations for CVS/pharmacy. "We are pleased to have once again teamed up with Access Hollywood to bring this contribution to these very worthy charities at this exciting event."

Celebrity representatives, Vanessa Hudgens ("High School Musical 3") and Taylor Lautner ("Twilight"), accepted the check from CVS/pharmacy on behalf of the two charities supported by Access Hollywood hosts Nancy O'Dell and Billy Bush.

The lounge, which opened Friday, January 9th and ran through Saturday, January 10th, featured hairstyling by celebrity stylist Cristophe, aromatherapy massages with Vickery &a
'/>"/>

SOURCE CVS/pharmacy
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. CVS/pharmacy Offers Shoppers More Than $69 Million in Extra Bucks
2. CVS/pharmacy and MinuteClinic Reach Goal of Delivering One Million Flu Vaccinations
3. CVS/pharmacy Raising Funds for the St. Jude Childrens Research Hospital(R) Thanks and Giving(R) Campaign to Support Expanded Rehabilitation Services Center
4. Video: CVS/pharmacy and National Council on Aging Help Seniors to Find the Right Prescription for Medicare Savings
5. CVS/pharmacy Helps Patients Manage Diabetes Care
6. CVS/pharmacy Launches Beauty 360
7. CVS/pharmacy Announces Pharmacy Health Care Savings Program Targeted at the Uninsured
8. CVS/pharmacy Re-Opens 64 Stores in Louisiana
9. CVS/pharmacy Raises Record-breaking $4.4 Million for ALS Research Through Annual ALS Fundraising Campaign
10. Howard University and CVS/pharmacy Announce Ribbon Cutting for the Howard University Pharmacy Practice Laboratory
11. CVS/pharmacy Delivers Disaster Relief in Iowa Communities Impacted by Recent Flooding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2009)... ReverseAges.com launches new content to include ...igue, and how to best deal with these health issue...) July 3, 2009 -- ReverseAges.com has recently lau...he dangers of common health issues such as high bl...ariety of factors, and the new content on ReverseA...
(Date:7/2/2009)...e,s Bioprocessing Technology Institute (BTI) have ...optosis inhibitory molecule" (FAIM), protects both...med cell death. , Their research is published i...ion . , The scientists, Jianxin Huo, Ph.D., and ...ss may possibly be manipulated for clinical applic...
(Date:7/2/2009)... July 2 Dr Daniel Goldberg, a lead...ew study to measure the effectiveness of using 5% ...a common, worldwide, highly contagious and often s...r long term visual impairment due to corneal invol...re invited to register to participate in the Betad...
(Date:7/2/2009)... down one set of neurons, another set wakes up: st...s) -- New information about brain circuit activity...ep aid Ambien (zolpidem) walk, eat, talk on the ph...thout remembering it the next morning. , The dr...us patients into a conscious state. , In experi...
Breaking Medicine News(10 mins):Health News:Gene's novel role may provide key to treating liver and neurodegenerative diseases 2Health News:Ophthalmologists Invited To Participate in Betadine for EKC Treatment Study 2Health News:Odd Behaviors on Ambien Linked to Brain Circuitry 2
...l problems and male impotence can be a thing of th...alled Cialis. Cialis takes you beyond the world of...lly proven to both work up to 36 hours and work in...utes from the time of the intake of the medicine. ...
...ior judge of Pakistan has ordered woman lawyers no... Times reported Saturday//. "You are professionals...ief Justice Tariq Pervaiz Khan of the Peshawar Hig...ees Anjum, ordering the ban on veils. "We (the jud...
... Minister Manmohan Singh Saturday promised a "forw...ring policy soon to help realise //late prime mini...ia. Inaugurating an industrial park set up here by...n Singh termed it as a tribute to the memory of Ra...
...apacity of an individual's immune system to contro...ific versions of key immune-system molecules// cal...as on the fragments of viral protein those molecul...roy infected cells. In a report in the November is...
Other Medicine News:Health News:Cialis- Bringing Respite To ED Effectively 2Health News:PM promises forward-looking IT, electronics policy soon 2Health News:Genes determine the capacity to fight HIV in early stages 2Health News:Genes determine the capacity to fight HIV in early stages 3
(Date:6/29/2009)...minal surgery patients achieved primary and second... AcelRx Pharmaceuticals, Inc. toda... 2 clinical study evaluating the safety and effica...anagement of acute post-operative pain in patients.... Compared to placebo, patients receiving ARX-01 S...
(Date:6/28/2009)...land and TOKYO, June 29 , -...s , Sosei Group Corporation ("Sosei"; TSE M...ra"; LSE: VEC) announce the commencement of a Phas...once-daily, long-acting muscarinic,antagonist (LA...nary disease,(COPD). NVA237 is a dry powder formu...
(Date:6/26/2009)...commends Approval of New Anti-TNF Therapy in Three...njector , , HORSHAM, Pa. and KENILWORTH, N.J., ...iotech Inc. and Schering-Plough Corporation (NYSE:...dicinal Products for Human Use (CHMP) of the Europ...nion recommending the approval of SIMPONI(TM) (gol...
(Date:6/25/2009)...A (TM) Data Highlighted at the College on Problems...v., June 25 King Pharmaceuticals...any is presenting safety and efficacy data for ACU... analgesic formulations that are in development, a...ms of Drug Dependence. King is also developing ot...
Breaking Medicine Technology:AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 2AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 3AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 4Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 2Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 2SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 3SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 4SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 5SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 6SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 7SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 8SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 9SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 10King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 2King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 3King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 4King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 5King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 6Viral Therapy Slows Pediatric Tumors in Mice 12024 1Viral Therapy Slows Pediatric Tumors in Mice 12024 2Milestone Scientific to Exhibit at the Chicago Dental Societys 143rd Midwinter Meeting 12022 1Milestone Scientific to Exhibit at the Chicago Dental Societys 143rd Midwinter Meeting 12022 2Milestone Scientific to Exhibit at the Chicago Dental Societys 143rd Midwinter Meeting 12022 3KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 1KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 2KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 3KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 4KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 5KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 6KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 7KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 8KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 9KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 10KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 11KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 12KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 13KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 14KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 15KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 16KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 17KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 18KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 19KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 20KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 21KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 22KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results 3B Receives Trading Extension From NYSE 12021 23Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results 3336 1Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results 3336 2Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results 3336 3Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results 3336 4Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results 3336 5Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results 3336 6Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results 3336 7Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results 3336 8
... Hypertension,Treatment Valsartan in Preventing Ca...pril 26, 2007 /Xinhua-PRNewswire/ -- The clinical,... clinical trial,headed by the Jikei University Sch...ationally renowned medical journal The,Lancet. The... of,the largest cardiovascular intervention trials...
...,Merck Serono S.A. (virt-x: SEO) and its partner N... today that Professor,Fabrizio Stocchi, MD, PhD, w...al of safinamide as an adjunctive treatment to,dop...ease (PD),patients at the American Academy of Neur...m 28 April to 5 May 2007. , The abstract entitled ...
Other Medicine Technology:First Controlled Large-Scale Intervention Angiotensin Receptor,Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study,Demonstrates Significant Reduction in Blood Pressure and Protection,of Organs with Valsartan 2First Controlled Large-Scale Intervention Angiotensin Receptor,Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study,Demonstrates Significant Reduction in Blood Pressure and Protection,of Organs with Valsartan 3First Controlled Large-Scale Intervention Angiotensin Receptor,Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study,Demonstrates Significant Reduction in Blood Pressure and Protection,of Organs with Valsartan 4Merck Serono Announces Presentation of Phase III Clinical Data on,Safinamide in Parkinson’s Disease at the American Academy of,Neurology 59th Annual Meeting 2Merck Serono Announces Presentation of Phase III Clinical Data on,Safinamide in Parkinson’s Disease at the American Academy of,Neurology 59th Annual Meeting 3Merck Serono Announces Presentation of Phase III Clinical Data on,Safinamide in Parkinson’s Disease at the American Academy of,Neurology 59th Annual Meeting 4
Shoulder rasp
12" suture passer
Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand
The ArthroPasser easily passes any type of suture through tissue and its smooth jaw assists in eliminating,suture fraying.
Medicine Products: